FISH MPN Eosinophilia (Fluorescence In Situ Hybridization for Myeloproliferative Neoplasms with Eosinophilia) is a cytogenetic test that uses fluorescent probes to detect specific chromosomal rearrangements associated with MPNs that often present with eosinophilia. These rearrangements typically involve tyrosine kinase genes like PDGFRA, PDGFRB, and FGFR1, and their identification can help diagnose specific subtypes of MPNs and guide treatment decisions.

This molecular test detects the presence or absence of the BCR-ABL1 fusion gene transcript in blood or bone marrow samples, typically from patients with suspected chronic myeloid leukemia (CML). It utilizes PCR to amplify the target sequence, providing a qualitative yes/no answer about the presence of this hallmark genetic abnormality in CML.

This molecular test accurately measures the amount of BCR-ABL1 fusion gene transcript in blood or bone marrow samples, typically from patients with chronic myeloid leukemia (CML). It uses real-time PCR to quantify the transcript levels, which helps assess treatment response, monitor minimal residual disease (MRD), and detect disease relapse.

The PML-RARA Qualitative Test detects the PML-RARA fusion gene using RT-PCR on blood or bone marrow samples. It aids in diagnosing acute promyelocytic leukemia (APL), monitoring treatment response, and detecting relapse. Positive results indicate the presence of the fusion gene.

The PML-RARA Quantitative Test measures the amount of PML-RARA fusion gene in blood or bone marrow samples using RT-PCR. It’s crucial for diagnosing acute promyelocytic leukemia (APL), monitoring treatment response (detecting minimal residual disease), and assessing relapse risk. Results provide a numerical value indicating the level of the fusion gene.

The PCR JAK2 V617F test is a molecular diagnostic test that detects and quantifies the JAK2 V617F mutation in blood or bone marrow. This mutation is associated with myeloproliferative neoplasms (MPNs). The test aids in diagnosis, prognosis (by measuring allele burden), and monitoring treatment response.

A tiered molecular test that detects mutations associated with myeloproliferative neoplasms (MPNs). It begins with JAK2 V617F mutation testing, and if negative, reflexively tests for other mutations like CALR and MPL. This helps diagnose specific types of MPNs and guide treatment decisions.

PCR leukemia tests detect and quantify specific genetic mutations or fusion genes associated with different types of leukemia. These tests aid in diagnosis, classification, prognosis assessment, monitoring treatment response, and detecting minimal residual disease (MRD) or relapse. Examples include BCR-ABL1 testing for chronic myeloid leukemia (CML), PML-RARA for acute promyelocytic leukemia (APL), and FLT3 for acute myeloid leukemia (AML).

This PCR-based molecular test simultaneously detects mutations in three genes—NPM1, FLT3-ITD, and CEBPA—that are crucial for classifying and predicting prognosis in acute myeloid leukemia (AML) patients. It aids in risk stratification, treatment selection, and monitoring minimal residual disease (MRD) in AML.

This PCR-based molecular test detects mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukemia (CML) who show resistance or inadequate response to imatinib (a tyrosine kinase inhibitor). It helps identify specific mutations responsible for drug resistance, guiding personalized treatment decisions and improving outcomes for CML patients.